Advertisement

Digestive Diseases and Sciences

, Volume 63, Issue 10, pp 2729–2739 | Cite as

Low Rates of Dermatologic Care and Skin Cancer Screening Among Inflammatory Bowel Disease Patients

  • Alyce Anderson
  • Laura K. Ferris
  • Benjamin Click
  • Claudia Ramos-Rivers
  • Ioannis E. Koutroubakis
  • Jana G. Hashash
  • Michael Dunn
  • Arthur Barrie
  • Marc Schwartz
  • Miguel Regueiro
  • David G. Binion
Original Article

Abstract

Background

Dermatologic manifestations of inflammatory bowel disease (IBD) are common, and certain IBD medications increase the risk of skin cancer.

Aims

To define the rates of care and factors associated with dermatologic utilization with a focus on skin cancer screening.

Methods

We utilized a prospective, natural history IBD research registry to evaluate all outpatient healthcare encounters from 2010 to 2016. Gastrointestinal, dermatologic and primary care visits per individual were identified. We calculated the proportion of patients obtaining care, categorized primary indications for dermatologic visits, determined the incidence of melanoma and non-melanoma skin cancers, and used logistic regression to determine factors associated with dermatology utilization.

Results

Of the 2127 IBD patients included, 452 (21.3%) utilized dermatology over the study period, and 55 (2.6%) had a total body skin examination at least once. The 452 patients incurred 1633 dermatology clinic visits, 278 dermatologic procedures, and 1108 dermatology telephone encounters. The most frequent indication was contact dermatitis or dermatitis. Factors associated with dermatology use were family history of skin cancer, employment, systemic steroids, longer disease duration, emergency room use, and the number of IBD-related clinic visits. Between 8.3 and 11% of IBD patients recommended for skin cancer screening visited dermatology each year, and the resulting incidence of non-melanoma skin cancer was 35.4/10,000 [95% CI 23.3–51.5] and melanoma was 6.56/10,000 [95% CI 2.1–15.3].

Conclusions

Less than one in ten IBD patients obtain dermatologic care. Given the increased risk of skin cancers among IBD patients, an emphasis on education, prevention, and screening merits attention.

Keywords

Inflammatory bowel disease Dermatology Dermatologic manifestations Skin cancer screening Preventative medicine 

Notes

Acknowledgment

We would like to acknowledge the faculty, staff, and most importantly the generosity of our patients who continue to make this research feasible.

Author’s contribution

Alyce Anderson, BS contributed to drafting of manuscript, data organization, statistical analysis, table and figure creation, manuscript revisions, and critical review of the manuscript. Laura Ferris, MD, PhD contributed to data review, advisor to primary author, project supervision, and critical review of the manuscript. Benjamin Click, MD contributed to drafting of manuscript, data collection, and critical review of the manuscript. Claudia Ramos-Rivers, MD contributed to data collection and organization, and critical review of the manuscript. Ioannis E. Koutroubakis, MD, PhD was involved in critical review of the manuscript, collection of data. Jana G. Hashash, MD helped in critical review of the manuscript, collection of data. Michael Dunn, MD contributed to critical review of the manuscript and collection of data. Arthur Barrie, MD, PhD was involved in critical review of the manuscript and collection of data. Marc Schwartz, MD helped in critical review of the manuscript and collection of data. Miguel Regueiro, MD contributed to critical review of the manuscript and collection of data. David Binion, MD helped in critical review of the manuscript, collection of data, and project supervision and was advisor to primary author. All authors read and approved the final manuscript.

Funding

Alyce Anderson is supported by an NIH training Grant (TL1TR001858, PI: Kapoor). David G. Binion reports support from Grant W81XWH-11-2-0133 from the U.S. Army Medical Research and Materiel Command. Laura K. Ferris is supported by a National Cancer Institute Grant (5P50CA121973-08). Research reported in this publication was supported by the National Center For Advancing Translational Sciences of the National Institutes of Health under Award Number TL1TR001858. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Compliance with ethical standards

Conflict of interest

Alyce Anderson, Laura K. Ferris, Benjamin Click, Claudia Ramos-Rivers, Ioannis E. Koutroubakis, Jana G. Hashash, Michael Dunn, Arthur Barrie, Marc Schwartz, Miguel Regueiro, and David G. Binion declare they have no conflict of interest.

Supplementary material

10620_2018_5056_MOESM1_ESM.docx (77 kb)
Supplementary material 1 (DOCX 76 kb)

References

  1. 1.
    Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;19:2066–2078.CrossRefGoogle Scholar
  2. 2.
    Trikudanathan G, Venkatesh PG, Navaneethan U. Diagnosis and therapeutic management of extra-intestinal manifestations of inflammatory bowel disease. Drugs. 2012;24:2333–2349.CrossRefGoogle Scholar
  3. 3.
    Hagen JW, Swoger JM, Grandinetti LM. Cutaneous manifestations of crohn disease. Dermatol Clin. 2015;33:417–431.CrossRefGoogle Scholar
  4. 4.
    Harbord M, Annese V, Vavricka SR, et al. The first european evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2016;10:239–254.CrossRefGoogle Scholar
  5. 5.
    Huang BL, Chandra S, Shih DQ. Skin manifestations of inflammatory bowel disease. Front Physiol. 2012;6:13.Google Scholar
  6. 6.
    Marzano AV, Borghi A, Stadnicki A, Crosti C, Cugno M. Cutaneous manifestations in patients with inflammatory bowel diseases: pathophysiology, clinical features, and therapy. Inflamm Bowel Dis. 2014;20:213–227.CrossRefGoogle Scholar
  7. 7.
    Weizman A, Huang B, Berel D, et al. Clinical, serologic, and genetic factors associated with pyoderma gangrenosum and erythema nodosum in inflammatory bowel disease patients. Inflamm Bowel Dis. 2014;20:525–533.CrossRefGoogle Scholar
  8. 8.
    Cleynen I, Van Moerkercke W, Billiet T, et al. Characteristics of skin lesions associated with anti-tumor necrosis factor therapy in patients with inflammatory bowel disease: a cohort study. Ann Intern Med. 2016;5:10–22.CrossRefGoogle Scholar
  9. 9.
    Pedersen N, Duricova D, Elkjaer M, Gamborg M, Munkholm P, Jess T. Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. Am J Gastroenterol. 2010;105:1480–1487.CrossRefGoogle Scholar
  10. 10.
    Kappelman MD, Farkas DK, Long MD, et al. Risk of cancer in patients with inflammatory bowel diseases: a nationwide population-based cohort study with 30 years of follow-up evaluation. Clin Gastroenterol Hepatol. 2014;12:e1.CrossRefGoogle Scholar
  11. 11.
    Singh S, Nagpal SJ, Murad MH, et al. Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014;12:210–218.CrossRefGoogle Scholar
  12. 12.
    Long MD, Martin CF, Pipkin CA, Herfarth HH, Sandler RS, Kappelman MD. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012;143:e1.CrossRefGoogle Scholar
  13. 13.
    Mariette X, Matucci-Cerinic M, Pavelka K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis. 2011;70:1895–1904.CrossRefGoogle Scholar
  14. 14.
    McKenna MR, Stobaugh DJ, Deepak P. Melanoma and non-melanoma skin cancer in inflammatory bowel disease patients following tumor necrosis factor-α inhibitor monotherapy and in combination with thiopurines: analysis of the Food and Drug Administration Adverse Event Reporting System. J Gastrointestin Liver Dis. 2014;23:267–271.PubMedGoogle Scholar
  15. 15.
    Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG clinical guideline: preventive care in inflammatory bowel disease. Am J Gastroenterol. 2017;112:241–258.CrossRefGoogle Scholar
  16. 16.
    Jensen P, Hansen S, Møller B, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol. 1999;40:177–186.CrossRefGoogle Scholar
  17. 17.
    Abbas AM, Almukhtar RM, Loftus EV, Lichtenstein GR, Khan N. Risk of melanoma and non-melanoma skin cancer in ulcerative colitis patients treated with thiopurines: a nationwide retrospective cohort. Am J Gastroenterol. 2014;109:1781–1793.CrossRefGoogle Scholar
  18. 18.
    Scott FI, Mamtani R, Brensinger CM, et al. Risk of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and nonmelanoma skin cancer. JAMA Dermatol. 2016;152:164–172.CrossRefGoogle Scholar
  19. 19.
    Clowry J, Sheridan J, Healy R, et al. Increased non-melanoma skin cancer risk in young patients with inflammatory bowel disease on immunomodulatory therapy: a retrospective single-centre cohort study. J Eur Acad Dermatol Venereol. 2017.  https://doi.org/10.1111/jdv.14105.CrossRefPubMedGoogle Scholar
  20. 20.
    Long MD, Herfarth HH, Pipkin CA, Porter CQ, Sandler RS, Kappelman MD. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2010;8:268–274.CrossRefGoogle Scholar
  21. 21.
    Saraiya M, Hall HI, Thompson T, et al. Skin cancer screening among U.S. adults from 1992, 1998, and 2000 National Health Interview Surveys. Prev Med. 2004;39:308–314.CrossRefGoogle Scholar
  22. 22.
    Coups EJ, Geller AC, Weinstock MA, Heckman CJ, Manne SL. Prevalence and correlates of skin cancer screening among middle-aged and older white adults in the United States. Am J Med. 2010;123:439–445.CrossRefGoogle Scholar
  23. 23.
    Anderson AJ, Click B, Ramos-Rivers C, et al. Development of an inflammatory bowel disease research registry derived from observational electronic health record data for comprehensive clinical phenotyping. Dig Dis Sci. 2016;61:3236–3245.CrossRefGoogle Scholar
  24. 24.
    Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal world congress of gastroenterology. Can J Gastroenterol. 2005;19:5A–36A.CrossRefGoogle Scholar
  25. 25.
    Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. The Lancet. 1980;8:514.CrossRefGoogle Scholar
  26. 26.
    Kozarek RA, Patterson DJ, Gelfand MD, Botoman VA, Ball TJ, Wilske KR. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med. 1989;1:353–356.CrossRefGoogle Scholar
  27. 27.
    Irvine EJ, Zhou Q, Thompson AK. The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn’s Relapse Prevention Trial. Am J Gastroenterol. 1996;91:1571–1578.PubMedGoogle Scholar
  28. 28.
    Crohn’s and Colitis Foundation Professional Education Committee Sub Group: CCFA Health Maintenance Checklist for Adult IBD Patients 2017.Google Scholar
  29. 29.
    Pandey N, Herrera HH, Johnson CM, MacCarthy AA, Copeland LA. Preventative care for patients with inflammatory bowel disease in the Veterans Health Administration. Medicine. 2016;95:e4012.CrossRefGoogle Scholar
  30. 30.
    Long MD, Porter CQ, Sandler RS, Kappelman MD. Suboptimal rates of cervical testing among women with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2009;7:549–553.CrossRefGoogle Scholar
  31. 31.
    Goldberg MS, Doucette JT, Lim HW, Spencer J, Carucci JA, Rigel DS. Risk factors for presumptive melanoma in skin cancer screening: American Academy of Dermatology National Melanoma/Skin Cancer Screening Program experience 2001–2005. J Am Acad Dermatol. 2007;57:60–66.CrossRefGoogle Scholar
  32. 32.
    Lindelöf B, Sigurgeirsson B, Gäbel H, Stern RS. Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol. 2000;143:513–519.PubMedGoogle Scholar
  33. 33.
    Robbins HA, Clarke CA, Arron ST, et al. Melanoma Risk and survival among organ transplant recipients. J Invest Dermatol. 2015;135:2657–2665.CrossRefGoogle Scholar
  34. 34.
    Cowen EW, Billingsley EM. Awareness of skin cancer by kidney transplant patients. J Am Acad Dermatol. 1999;40:697–701.CrossRefGoogle Scholar
  35. 35.
    Ali FR, Samarasinghe V, Russell SA, Lear JT. Increasing capacity for skin surveillance in a transplant review clinic. Transplantation. 2014;97:e48–e50.CrossRefGoogle Scholar
  36. 36.
    Lloyd A, Klintmalm G, Qin H, Menter A. Skin cancer evaluation in transplant patients: a physician opinion survey with recommendations. Clin Transplant. 2015;29:110–117.CrossRefGoogle Scholar
  37. 37.
    Williams NC, Tong A, Howard K, Chapman JR, Craig JC, Wong G. Knowledge, beliefs and attitudes of kidney transplant recipients regarding their risk of cancer. Nephrology (Carlton). 2012;17:300–306.CrossRefGoogle Scholar
  38. 38.
    Wisgerhof HC, van der Geest LG, de Fijter JW, et al. Incidence of cancer in kidney-transplant recipients: a long-term cohort study in a single center. Cancer Epidemiol. 2011;35:105–111.CrossRefGoogle Scholar
  39. 39.
    Jess T, Horváth-Puhó E, Fallingborg J, Rasmussen HH, Jacobsen BA. Cancer risk in inflammatory bowel disease according to patient phenotype and treatment: a Danish population-based cohort study. Am J Gastroenterol. 2013;108:1869–1876.CrossRefGoogle Scholar
  40. 40.
    Scotto J, Kopf AW, Urbach F. Non-melanoma skin cancer among Caucasians in four areas of the United States. Cancer. 1974;34:1333–1338.CrossRefGoogle Scholar
  41. 41.
    Cheng MY, Moreau JF, McGuire ST, Ho J, Ferris LK. Melanoma depth in patients with an established dermatologist. J Am Acad Dermatol. 2014;70:841–846.CrossRefGoogle Scholar
  42. 42.
    Kirsner RS, Muhkerjee S, Federman DG. Skin cancer screening in primary care: prevalence and barriers. J Am Acad Dermatol. 1999;41:564–566.PubMedGoogle Scholar
  43. 43.
    Oliveria SA, Christos PJ, Marghoob AA, Halpern AC. Skin cancer screening and prevention in the primary care setting: national ambulatory medical care survey 1997. J Gen Intern Med. 2001;16:297–301.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Alyce Anderson
    • 1
  • Laura K. Ferris
    • 2
  • Benjamin Click
    • 3
  • Claudia Ramos-Rivers
    • 3
  • Ioannis E. Koutroubakis
    • 3
  • Jana G. Hashash
    • 3
  • Michael Dunn
    • 3
  • Arthur Barrie
    • 3
  • Marc Schwartz
    • 3
  • Miguel Regueiro
    • 3
  • David G. Binion
    • 3
  1. 1.University of Pittsburgh School of MedicinePittsburghUSA
  2. 2.Department of DermatologyUniversity of Pittsburgh Medical CenterPittsburghUSA
  3. 3.Division of Gastroenterology, Hepatology, and NutritionUniversity of Pittsburgh Medical CenterPittsburghUSA

Personalised recommendations